Semaglutide in pill form: what the UK approval actually means

From injection to tablet: what the MHRA's June 2026 decision confirmed

The MHRA's approval of Wegovy tablets on 11 June 2026 settled a question many people had been asking for months: when would an oral version of Wegovy reach the UK? The answer turned out to be sooner than most expected, and the UK beat the rest of Europe to it. The tablet formulation combines semaglutide with an absorption enhancer called SNAC, which allows the molecule to cross the stomach lining into the bloodstream, something earlier oral semaglutide research had to solve before a weight-management product was viable.

The OASIS 4 phase-3 trial, which underpinned the approval, enrolled 307 adults with obesity or overweight alongside at least one weight-related condition, without type 2 diabetes, over 64 weeks. Participants taking the 25mg tablet alongside lifestyle changes lost around 13.6% of body weight on average, compared with around 2.4% on placebo. Among those who stayed fully adherent throughout, the average reached roughly 16.6%, though that figure applies specifically to consistent users, not the group as a whole, so it is worth keeping both numbers in view. The MHRA's published approvals page sets out the regulatory basis for both the tablet and the higher-dose 7.2mg injection pen approved earlier in 2026.

One practical point the approval confirmed: patients already established on the 2.4mg weekly injection may move directly to the 25mg tablet, subject to a prescriber's assessment. The dose ladder does not have to restart from scratch in that scenario, though clinical review before any switch is essential.

How the tablet differs from the Wegovy injection, and from Rybelsus

If you have been researching whether oral semaglutide was available for weight loss, you may have come across Rybelsus and wondered whether that was the answer. It is not. Rybelsus contains oral semaglutide at 3mg, 7mg and 14mg, strengths licensed by the MHRA for type 2 diabetes, not weight management. The Wegovy tablet schedule is entirely separate: 1.5mg, 4mg, 9mg, then 25mg, and if you want a fuller picture of how the pill form of semaglutide works and what distinguishes it from other formulations, that is worth reading before drawing conclusions. Mixing up the two products is a genuine risk when reading general information online, so the distinction matters.

The injection form of Wegovy remains the longer-established option. Its clinical record in the UK stretches back further, and the NICE appraisal (TA875) covers the injection. The tablet does not yet have a NICE recommendation; a separate appraisal process would be required, which means it is not available on the NHS at launch and is, for now, a private prescription route only.

Mechanistically, both are GLP-1 receptor agonists: they act on receptors in the gut and brain that regulate appetite and gastric emptying, reducing hunger and slowing how quickly the stomach clears. The difference is format and frequency. The injection is once weekly; the tablet is once daily, and current UK availability of the tablet form is through private prescribers while NICE appraisal is pending.

There is also a practical ritual to the tablet that the injection does not require. It goes down first thing in the morning with a sip of plain water (up to around 120ml) before anything else: food, coffee, other oral medicines. You then wait at least 30 minutes before eating or drinking anything further. That window matters for absorption; skipping it consistently would reduce how much active drug gets in. On the other hand, no fridge is needed, which many people find simpler for travel and daily routine.

Who the tablet is licensed for, and what a prescriber weighs up

The licensed eligibility criteria for Wegovy tablets follow a similar pattern to the injection: adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance. BMI alone does not settle the decision, a prescriber reviews the whole picture, including current medications, relevant medical history and whether there are any contraindications.

The medicine is not suitable during pregnancy, breastfeeding or when actively trying to conceive. It is not licensed for anyone under 18. People with a history of medullary thyroid carcinoma or MEN2, or with active pancreatitis, are among those for whom a prescriber would not proceed.

If you are curious about costs alongside clinical fit, a breakdown of what private Wegovy tablet treatment involves financially is worth reading before starting a consultation. As with all prescription-only medicines, the legal route to the tablet is a clinical assessment from a registered prescriber, not a purchase from an unverified online seller. Anyone offering it without requiring that process is a red flag worth reporting to the MHRA's Yellow Card service at yellowcard.mhra.gov.uk.

The most common side effects in the OASIS 4 trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation were reported by a significant proportion of tablet users, though they were generally mild to moderate and tended to ease over time. They follow the pattern seen with the injection, and slow dose escalation exists precisely to give the body time to adjust. If you want to talk through whether the tablet or injection is likely to suit your situation better, starting a free consultation with our prescribers is the sensible next step, a real clinician reviews your answers, not a scoring algorithm.